Larry S. Schlesinger, MD is an internationally recognized authority in infectious diseases with a particular interest in tuberculosis and lung biology. He will begin his tenure as President/CEO of Texas Biomed May 31, 2017.
He earned a BA in Biology from Cornell University and MD from Rutgers Medical School. He completed his residency in Internal Medicine at the University of Michigan and clinical and research fellowships in Infectious Diseases at UCLA. He joined the faculty at the University of Iowa in 1991 where he served as Fellowship Director for the Division of Infectious Diseases and Associate Chair of the Department of Medicine. He moved to the Ohio State University in 2002 where he served as Director of the Division of Infectious Diseases, Department of Internal Medicine until 2011 when he became chair of Microbial Infection & Immunity.
Dr. Schlesinger is a leading physician scientist whose studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms. His discoveries have led to greater insight into the unique attributes that soluble and cellular components of the innate immune system of humans bring to the microbe-host interface, translating them into drug discovery platforms. He is a prolific scholar, having authored more than 170 peer-reviewed articles, served as editor of 2 books and has written several chapters in leading textbooks on tuberculosis and lung biology. He has been continually funded for nearly 30 years by the National Institutes of Health (NIH) and other federal agencies as well as private foundations such as the Bill & Melinda Gates Foundation.
He is a current NIH NIAID Council member, Fellow of the American Association for the Advancement of Science, Association of American Physicians and American Academy of Microbiology, and OSU’s 2011 Distinguished Scholar and 2015 COM Distinguished Professor.
Dr. Schlesinger has placed great emphasis on education and mentoring throughout his career, particularly in clinical and translational research, and has been committed to building strong interdisciplinary academic programs. He has been/is a faculty member of 10 pre- and post-doctoral training programs (NIH and HHMI) and is PI of 2 NIH T32 training grants, including the MSTP. In all, he has mentored ~170 trainees at all levels, several of whom have been awarded national research fellowships (36 in total) and have gone on to academic or industry positions. He became director of the OSU Medical Scientist Program (MD PhD granting) in 2008 and was awarded the first ever NIH-funded MSTP in 2011 (renewed in 2016). He is a current member of the AAMC GREAT MD-PhD Section Steering Committee and chair-elect of this group.